Package Leaflet: Information for the Patient
Brivaracetam Viso Pharmaceutical 10 mg film-coated tablets EFG
Brivaracetam Viso Pharmaceutical 25 mg film-coated tablets EFG
Brivaracetam Viso Pharmaceutical 50 mg film-coated tablets EFG
Brivaracetam Viso Pharmaceutical 75 mg film-coated tablets EFG
Brivaracetam Viso Pharmaceutical 100 mg film-coated tablets EFG
Read the entire package leaflet carefully before starting to take this medication, as it contains important information for you.
What is Brivaracetam Viso Pharmaceutical
Brivaracetam Viso Pharmaceutical contains the active substance brivaracetam. It belongs to a group of medications called "antiepileptics". These medications are used to treat epilepsy.
What is Brivaracetam Viso Pharmaceutical used for
Severe skin reactions, including Stevens-Johnson syndrome, have been reported with brivaracetam treatment. Do not take brivaracetam and consult your doctor immediately if you notice any of the symptoms related to these severe skin reactions described in section 4.
Consult your doctor or pharmacist before starting to take brivaracetam:
Brivaracetam is not recommended for use in children under 2 years of age.
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medications.
In particular, tell your doctor if you are taking any of the following medications, as your doctor may need to adjust your brivaracetam dose:
Women of childbearing age should discuss the use of contraceptives with their doctor.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
It is not recommended to take brivaracetam if you are pregnant, as the effects of brivaracetam on pregnancy and the fetus are unknown.
It is not recommended to breastfeed your baby while taking brivaracetam, as brivaracetam is excreted in breast milk.
Do not stop treatment without consulting your doctor first. Stopping treatment could increase the number of seizures you have and harm your baby.
This medication contains less than 1 mmol of sodium (23 mg) per tablet; it is essentially "sodium-free".
Follow your doctor's instructions for taking this medication exactly. If you are unsure, consult your doctor or pharmacist again. Other forms of this medication may be more suitable for some patients, e.g., children (if they cannot swallow whole tablets, for example). Consult your doctor or pharmacist.
You will take brivaracetam in combination with other medications to treat epilepsy.
Dose
Your doctor will calculate the correct daily dose for you. Take the daily dose divided into two equal doses, approximately 12 hours apart.
Adolescents and children weighing 50 kg or more, and adults
Adolescents and children weighing between 20 kg and less than 50 kg
Children weighing between 10 kg and less than 20 kg
Patient with liver problems
If you have liver problems:
Brivaracetam is a long-term treatment - continue taking this medication until your doctor tells you to stop.
If you take more brivaracetam than you should, consult your doctor. You may feel dizzy and drowsy. You may also experience some of the following symptoms: feeling unwell, feeling like you are spinning, balance problems, anxiety, feeling very tired, irritability, aggression, difficulty sleeping, depression, thoughts or attempts to harm yourself or commit suicide.
If you have any further questions about the use of this medication, ask your doctor or pharmacist.
Like all medications, this medication can cause side effects, although not everyone gets them.
Very common:may affect more than 1 in 10 people.
Common:may affect up to 1 in 10 people.
Uncommon:may affect up to 1 in 100 people
Frequency not known:cannot be estimated from the available data
Common:may affect up to 1 in 10 people.
If you experience any side effects, consult your doctor or pharmacist, even if they are not listed in this package leaflet. You can also report side effects directly through the Spanish Medicines Monitoring System: www.notificaRAM.es. By reporting side effects, you can help provide more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date stated on the package and blister after EXP. The expiration date is the last day of the month indicated.
This medication does not require special storage conditions.
Medications should not be disposed of via wastewater or household waste. Place the packaging and any unused medication in the SIGRE collection point at your pharmacy. Ask your pharmacist how to dispose of the packaging and any unused medication. This will help protect the environment.
Core: microcrystalline cellulose, pregelatinized starch (from corn), sodium croscarmellose, magnesium stearate (see section 2, "Brivaracetam Viso Pharmaceutical contains sodium").
Tablet coating:
Brivaracetam Viso Pharmaceutical 10 mg are white or almost white, round, biconvex, 6 mm in diameter, engraved with "10" on one side.
Brivaracetam Viso Pharmaceutical 25 mg are gray, oval, biconvex, 9 x 5 mm, engraved with "25" on one side.
Brivaracetam Viso Pharmaceutical 50 mg are yellow, oval, biconvex, 12 x 7 mm, engraved with "50" on one side.
Brivaracetam Viso Pharmaceutical 75 mg are pink, oval, biconvex, 13 x 7 mm, engraved with "75" on one side.
Brivaracetam Viso Pharmaceutical 100 mg are gray-green, oval, biconvex, 15 x 8 mm, engraved with "100" on one side.
Brivaracetam Viso Pharmaceutical tablets are packaged in blisters included in cardboard boxes containing 14 or 56 film-coated tablets, or 100 x 1 film-coated tablets in single-dose blisters.
The 10 mg, 25 mg, 50 mg, and 75 mg film-coated tablets may also be packaged in multiple packages containing 168 (2 packages of 84) film-coated tablets.
The 100 mg film-coated tablets may also be packaged in multiple packages containing 168 (3 packages of 56) film-coated tablets.
All packages are available in aluminum/aluminum (OPA/aluminum/PVC) blisters.
Not all package sizes may be marketed.
Marketing authorization holder
Glenmark Arzneimittel GmbH
Industriestr. 31
82194 Gröbenzell
Germany
Holsten Pharma GmbH
Hahnstraße 31-35
60528 Frankfurt am Main
Germany
You can obtain further information on this medication by contacting the local representative of the marketing authorization holder:
Viso Farmacéutica S.L.U.
C/ Retama 7, 7th floor
28045 Madrid
Spain
This medication is authorized in the Member States of the European Economic Area under the following names:
Germany Brivaracetam Glenmark 10 mg film-coated tablets
Brivaracetam Glenmark 25 mg film-coated tablets
Brivaracetam Glenmark 50 mg film-coated tablets
Brivaracetam Glenmark 75 mg film-coated tablets
Brivaracetam Glenmark 100 mg film-coated tablets
Denmark Brivaracetam Glenmark
Spain Brivaracetam Viso Farmacéutica 10 mg film-coated tablets EFG
Brivaracetam Viso Farmacéutica 25 mg film-coated tablets EFG
Brivaracetam Viso Farmacéutica 50 mg film-coated tablets EFG
Brivaracetam Viso Farmacéutica 75 mg film-coated tablets EFG
Brivaracetam Viso Farmacéutica 100 mg film-coated tablets EFG
Finland Brivaracetam Glenmark 10 mg film-coated tablets
Brivaracetam Glenmark 25 mg film-coated tablets
Brivaracetam Glenmark 50 mg film-coated tablets
Brivaracetam Glenmark 75 mg film-coated tablets
Brivaracetam Glenmark 100 mg film-coated tablets
Italy Brivaracetam Glenmark 10 mg film-coated tablets
Brivaracetam Glenmark 25 mg film-coated tablets
Brivaracetam Glenmark 50 mg film-coated tablets
Brivaracetam Glenmark 75 mg film-coated tablets
Brivaracetam Glenmark 100 mg film-coated tablets
Netherlands Brivaracetam Glenmark 10 mg film-coated tablets
Brivaracetam Glenmark 25 mg film-coated tablets
Brivaracetam Glenmark 50 mg film-coated tablets
Brivaracetam Glenmark 75 mg film-coated tablets
Brivaracetam Glenmark 100 mg film-coated tablets
Norway Brivaracetam Glenmark
Sweden Brivaracetam Glenmark
Slovak Republic Brivaracetam Glenmark 10 mg
Brivaracetam Glenmark 25 mg
Brivaracetam Glenmark 50 mg
Brivaracetam Glenmark 75 mg
Brivaracetam Glenmark 100 mg
Detailed information on this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/).